Understanding how obesity affects asthma treatment in children
Official title: Systemic Corticosteroid Pharmacokinetics and Pharmacodynamic Biomarker Identification in Children with Asthma and Obesity
Funded at Children's Mercy Hosp (Kansas City, Mo) · NIH-11054439 · Data updated 2026-11-12
This study is looking at how being overweight might change how well asthma medications work for kids, so we can find better ways to treat asthma in children who are obese.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Mercy Hosp (Kansas City, Mo) NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $188,073 |
| NIH project number | 1K23HL173648-01A1 |
| Project ID | NIH-11054439 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who have been diagnosed with asthma and are also experiencing obesity.
✕Less likely to help
Patients without asthma or those who do not have obesity may not benefit from this research.
What this research studies
This research investigates how obesity influences the effectiveness and safety of systemic corticosteroids used to treat asthma in children. By focusing on pharmacokinetics (how the body processes medication) and pharmacodynamics (how the medication affects the body), the study aims to identify biomarkers that can help tailor asthma treatments for children with obesity. The research will involve analyzing the unique asthma characteristics in these children, which may lead to more personalized and effective treatment strategies. Dr. Kathryn Kyler, the principal investigator, will utilize her expertise to enhance understanding of these relationships over a five-year period.
Why it matters
Potential benefit: If successful, this research could lead to more effective asthma treatments specifically designed for children with obesity, improving their health outcomes.
How similar studies have gone: Previous research has shown promising results in understanding the pharmacokinetics and pharmacodynamics of medications in pediatric populations, indicating that this approach could yield valuable insights.
Where this research is happening
-
Children's Mercy Hosp (Kansas City, Mo)
Kansas City, United States Active
Researchers
- Principal investigator: Kyler, Kathryn Ellen Dotts — Children's Mercy Hosp (Kansas City, Mo)
- Study coordinator: Kyler, Kathryn Ellen Dotts
Related research
Other NIH-funded projects on the same topics.
-
GLP-1 receptor agonists as immune targets to treat asthma in lean and obese adults
Aims to understand how GLP-1R‑agonist diabetes medicines may directly calm immune cells to reduce asthma in adults who are lean or obese.
-
Semaglutide for adults with obesity-related asthma
This trial gives adults with obesity-related asthma a daily oral semaglutide pill to test whether it improves asthma control and lowers airway and fat-tissue inflammation.
-
GLP-1R drugs as a new approach for asthma in different body types
Researchers are testing whether popular diabetes drugs that activate GLP-1 receptors can reduce airway inflammation and help adults with asthma, including those who are lean or overweight.
-
How high insulin in obesity may make airways tighten in asthma
This project looks at whether the higher insulin that comes with obesity makes airway nerves cause tighter breathing in people with obesity-related asthma.
-
Understanding how GLP-1 medicines help with asthma in people who are lean or have obesity
This project aims to discover how existing GLP-1 medicines, used for diabetes and obesity, can also help reduce inflammation in people with asthma.
-
Investigating a new treatment for asthma in adults with obesity
This study is looking at how a medication called GLP-1RA might help adults with asthma related to obesity by improving their breathing and reducing inflammation, and if you join, you'll take either the medication or a placebo for 12 weeks to see how it works for you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.